Cannabis and Sleep: A Proposed Self-Reinforcing Cycle That May Worsen Both

A 2025 narrative review maps a conceptual model in which sleep problems drive cannabis self-medication and cannabis use neurobiologically worsens sleep, potentially escalating toward use disorder, though the unified causal pathway remains theoretical and has not been empirically tested as a whole.

Why This Matters

Sleep disorders affect tens of millions of Americans, and cannabis is now the most commonly used federally illicit substance in the country. As legalization expands, a growing number of adults report using cannabis specifically to help them sleep. Yet clinical guidance on whether this practice is beneficial, neutral, or harmful remains remarkably thin. Understanding whether cannabis and sleep problems interact in a self-reinforcing cycle has direct implications for how clinicians counsel patients who are already self-medicating, particularly as commercial cannabis products are marketed with sleep-promoting claims that outpace the evidence.

Clinical Summary

Sleep problems and cannabis use each represent significant public health concerns independently. Their intersection, however, has received less structured attention. A 2025 narrative review published in Sleep Medicine Reviews by Vandrey, Conroy, and colleagues synthesizes two largely separate literatures to propose a bidirectional feed-forward model. The mechanistic logic is straightforward: sleep disturbances, particularly shorter duration, irregular timing, and evening circadian preference, may motivate cannabis self-medication. Cannabis acutely produces sedative effects that subjectively reinforce its use as a sleep aid. However, the endocannabinoid system undergoes predictable neuroadaptive changes with repeated exposure, including CB1 receptor downregulation, which the authors hypothesize progressively undermines sleep architecture and maintains or worsens the original sleep complaint.

The review cites epidemiological data suggesting that up to 25% of U.S. adults use cannabis occasionally or regularly for sleep, with rates considerably higher in heavy-using emerging adult samples. Longitudinal studies referenced by the authors indicate that adolescent sleep disturbances prospectively predict earlier cannabis initiation and subsequent use disorder. The key limitation is that this bidirectional cycle has not been tested as a unified causal pathway in any single study or meta-analysis. The review itself uses narrative rather than systematic methods, with no predefined search protocol, no study count, and no formal quality appraisal of cited evidence. The authors explicitly frame their model as hypothesis-generating and call for population-level epidemiology, longitudinal bidirectional testing, and investigation of social determinants as next steps before clinical recommendations can be formalized.

Dr. Caplan’s Take

This review does something genuinely useful: it gives a name and a structure to a pattern many of us see regularly in practice. Patients come in already using cannabis for sleep, often with the conviction that it works. And acutely, they are not wrong. The problem is that the short-term subjective benefit may obscure a longer-term neurobiological trajectory toward tolerance and worsening sleep. What this paper provides is a framework for thinking about that trajectory, not proof that it unfolds in every patient. The honest answer to the patient who asks whether cannabis is helping their sleep is that we do not yet have enough rigorous evidence to say definitively, and that the existing biology raises real concerns about sustained use.

In my practice, I treat these conversations as opportunities for shared decision-making grounded in what we actually know. I discuss the plausibility of tolerance development and the distinction between subjective sleep improvement and objective sleep architecture. For patients already using cannabis for sleep, I focus on sleep hygiene optimization, structured behavioral approaches like CBT-I, and, where appropriate, gradual dose reduction with monitoring. I do not dismiss their experience, but I do not endorse escalation either. This review gives me a more organized way to explain the concern.

Clinical Perspective

This review sits early in the research arc for the cannabis-sleep relationship. It consolidates observational and mechanistic evidence into a testable conceptual model but does not itself validate that model. Clinicians should understand that the bidirectional cycle is biologically plausible and consistent with what is known about endocannabinoid system neuroadaptation, but it has not been confirmed through prospective studies designed to isolate the proposed feedback loop. The evidence supports discussing the possibility of tolerance-driven sleep worsening with patients, but it does not yet support definitive claims that cannabis universally degrades sleep or that cessation reliably restores it. The heterogeneity of cannabis products, dosing, cannabinoid ratios, and routes of administration further complicates any blanket recommendation.

From a pharmacological standpoint, clinicians should be attentive to the potential for cannabis to interact with other sedating medications, including benzodiazepines, gabapentinoids, and sedating antidepressants, as additive central nervous system depression is a realistic concern. THC-dominant products are more likely to produce the acute sedative effects patients seek, while the role of CBD in sleep remains poorly characterized at commonly used doses. The most actionable step clinicians can take now is to routinely screen for cannabis use when evaluating sleep complaints, ask specifically about self-medication motives, and document product type and frequency. This creates a foundation for monitoring and for revisiting the conversation as stronger evidence emerges.

Study at a Glance

Study Type

Narrative review with conceptual model proposal

Population

Non-clinical human samples across the lifespan, with emphasis on adolescents and emerging adults

Intervention

Cannabis use for sleep (self-medication behavior)

Comparator

Not applicable (no comparative design)

Primary Outcomes

Proposed bidirectional feed-forward cycle linking sleep disturbance, cannabis self-medication, neurobiological tolerance, and escalating use

Sample Size

Not applicable (no original data collected)

Journal

Sleep Medicine Reviews

Year

2025

DOI or PMID

Published January 3, 2025; specific DOI not provided in source material

Funding Source

Not reported in available metadata

What Kind of Evidence Is This

This is a narrative review, which sits below systematic reviews and meta-analyses in the evidence hierarchy. It synthesizes existing literature without a predefined search protocol, explicit inclusion and exclusion criteria, or formal quality appraisal of cited studies. The most important inference constraint this imposes is that the completeness and representativeness of the evidence base cannot be independently verified, meaning the proposed model may reflect selective citation rather than the full weight of available research.

How This Fits With the Broader Literature

The proposed model parallels established frameworks for the alcohol-sleep bidirectional relationship, where self-medication with alcohol for insomnia is well documented to worsen sleep architecture over time. In the cannabis domain, prior work by Babson and colleagues (2017) reviewed cannabis and sleep but stopped short of proposing a unified cyclical model with explicit escalation dynamics. The current review extends that foundation by integrating developmental trajectories and endocannabinoid tolerance mechanisms into a single framework. It aligns with neuroimaging studies showing CB1 receptor downregulation with chronic cannabis use and with epidemiological findings linking adolescent sleep problems to substance use initiation, though neither literature was systematically appraised here.

Common Misreadings

The most likely overinterpretation is treating the proposed feed-forward cycle as established causal fact. The model is conceptual. It organizes existing evidence into a plausible and testable framework, but no single study has prospectively demonstrated that sleep problems cause cannabis self-medication which in turn neurobiologically worsens sleep and escalates use in a continuous loop. Readers should also resist interpreting the prevalence figures (up to 25% of adults using cannabis for sleep) as precise point estimates; these are drawn from heterogeneous studies with differing definitions of cannabis use, sleep aid use, and target populations.

Bottom Line

This narrative review offers a coherent conceptual model for how sleep problems and cannabis use may reinforce each other over time, grounded in plausible neurobiology and consistent with available observational data. It does not, however, establish that this cycle operates as described. Its clinical value lies in providing a framework for patient conversations about cannabis and sleep, while its scientific value lies in defining a research agenda. Practice should not change on the basis of this review alone, but it strengthens the case for routinely screening for cannabis use in sleep evaluations.

References

1. Vandrey R, Conroy DA, et al. Cannabis use and sleep: a bidirectional feed-forward model. Sleep Medicine Reviews. Published online January 3, 2025.
2. Babson KA, Sottile J, Morabito D. Cannabis, cannabinoids, and sleep: a review of the literature. Current Psychiatry Reports. 2017;19(4):23. doi:10.1007/s11920-017-0775-9
3. D’Souza DC, Cortes-Briones JA, Ranganathan M, et al. Rapid changes in CB1 receptor availability in cannabis dependent males after abstinence from cannabis. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging. 2016;1(1):60-67. doi:10.1016/j.bpsc.2015.09.008